The performance of vibration controlled transient elastography in a US cohort of patients with nonalcoholic fatty liver disease

American Journal of Gastroenterology

Volumn 111, Issue 5, 2016, Pages 677-684

  Tapper, Elliot B ^a   Challies, Tracy ^a   Nasser, Imad ^a   Afdhal, Nezam H ^a   Lai, Michelle ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ADULT; ADVANCED LIVER FIBROSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIGESTIVE SYSTEM DISEASE ASSESSMENT; ELASTOGRAPHY; FEMALE; FOLLOW UP; HEPATOBILIARY PARAMETERS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER STIFFNESS MEASUREMENT; LOW RISK PATIENT; M PROBE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE FIBROSIS SCORE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RELIABILITY; SENSITIVITY AND SPECIFICITY; ULTRASOUND TRANSDUCER; UNITED STATES; VIBRATION CONTROLLED TRANSIENT ELASTOGRAPHY; WEIGHT REDUCTION; BIOPSY; DECISION TREE; DIAGNOSTIC IMAGING; PATHOLOGY; PREDICTIVE VALUE; REPRODUCIBILITY;

ADULT; BIOPSY; DECISION TREES; ELASTICITY IMAGING TECHNIQUES; FEMALE; HUMANS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 84961223692     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2016.49     Document Type: Article

References (32)

1. Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among US adults: NHANES III to NHANES 1999-2006. Diabetes Care 2011; 34: 216-9
2. Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012; 143: 1179-87
3. Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease specifi c mortality in NAFLD after up to 33 years of followup. Hepatology 2015; 61: 1547-54
4. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-23
5. Foster G, Goldin R, Main J, et al. Management of chronic hepatitis C: clinical audit of biopsy based management algorithm. BMJ 1997; 315: 453-8
6. Pasha T, Gabriel S, Therneau T, et al. Cost Effectiveness of ultrasoundguided liver biopsy. Hepatology 1998; 27: 1220-6
7. Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology 2009; 49: 1017-44
8. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57
9. Tapper EB, Castera L, Afdhal NH. FibroScan (Vibration Controlled Transient Elastography): where does it stand in the US practice. Clin Gastroenterol Hepatol 2015; 13: 27-36
10. Petta S, Vanni E, Bugianesi E, et al. The combination of liver stiff ness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. Liver Int 2015; 35: 1566-73
11. Kwok R, Tse YK, Wong GH, et al. Systematic review with meta analysis: non invasive assessment of non alcoholic fatty liver disease-the role of transient elastography and plasma cytokeratin 18 fragments. Aliment Pharmacol Ther 2014; 39: 254-69
12. Myers RP, Pomier Layrargues G, Kirsch R, et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiff ness measurement in overweight and obese patients. Hepatology 2012; 55: 199-208
13. Wong VW-S, Vergniol J, Wong GL-H, et al. Liver stiff ness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2012; 107: 1862-71
14. Tapper EB, Lai M. Weight loss results in signifi cant improvements in quality of life for patients with nonalcoholic fatty liver disease: a prospective cohort study. Hepatology 2015 Dec 23 [e-pub ahead of print
15. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21
16. Tapper EB, Afdhal NH. Vibration-controlled transient elastography: a practical approach to the noninvasive assessment of liver fibrosis. Curr Opin Gastroenterol 2015; 31: 192-8
17. Arena U, Lupsor Platon M, Stasi C, et al. Liver stiff ness is Influenced by a standardized meal in patients with chronic hepatitis C virus at diff erent stages of fibrotic evolution. Hepatology 2013; 58: 65-72
18. Petta S, Maida M, Macaluso FS, et al. The severity of steatosis Influences liver stiff ness measurement in patients with nonalcoholic fatty liver disease. Hepatology 2015; 62: 1101-10
19. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifi es liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-54
20. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005; 112: 2735-52
21. Dowman JK, Tomlinson J, Newsome P. Systematic review: the diagnosis and staging of non alcoholic fatty liver disease and non alcoholic steatohepatitis. Aliment Pharmacol Ther 2011; 33: 525-40
22. Harrison SA, Fecht W, Brunt EM, et al. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 2009; 49: 80-6
23. Petta S, Di Marco V, Camma C, et al. Reliability of liver stiff ness measurement in non alcoholic fatty liver disease: the Effects of body mass index. Aliment Pharmacol Ther 2011; 33: 1350-60
24. McPherson S, Stewart SF, Henderson E, et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010; 59: 1265-9
25. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long term follow up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-73
26. Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015; 13: 643-54
27. Tapper EB, Sengupta N, Hunink MM, et al. Cost-Effective evaluation of nonalcoholic fatty liver disease with NAFLD fibrosis score and vibration controlled transient elastography. Am J Gastroenterol 2015; 110: 1298-304
28. Castera L, Foucher J, Bernard PH, et al. Pitfalls of liver stiff ness measurement: a 5 year prospective study of 13,369 examinations. Hepatology 2010; 51: 828-35
29. Afdhal NH, Bacon BR, Patel K, et al. Accuracy of fi broscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a US multi-center study. Clin Gastroenterol Hepatol 2015; 13: 772-79
30. Nascimbeni F, Lebray P, Fedchuk L, et al. Signifi cant variations in elastometry measurements made within short-term in patients with chronic liver diseases. Clin Gastroenterol Hepatol 2015; 13: 763-71
31. Kwok R, Choi KC, Wong GL-H, et al. Screening diabetic patients for nonalcoholic fatty liver disease with controlled attenuation parameter and liver stiff ness measurements: a prospective cohort study. Gut; advance online publication, 14 April 2015 [e-pub ahead of print
32. Wong VWS, Vergniol J, Wong GLH, et al. Diagnosis of fibrosis and cirrhosis using liver stiff ness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51: 454-62